Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Ductal × exemestane × Breast × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 225 Neoplasm Metastasis 17 Breast Neoplasms, Male 7 Neoplasms 6 Breast Diseases 6 Carcinoma, Intraductal, Noninfiltrating 4 Recurrence 3 Obesity 3 Breast Carcinoma In Situ 3 Breast Cancer Metastatic 3 Advanced Breast Cancer 3 Neoplasms by Site 2 Bulbo-Spinal Atrophy, X-Linked 2 Arthralgia 2 Vitamin D Deficiency 1 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Triple Negative Breast Neoplasms 1 Thoracic Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sleep Wake Disorders 1 Skin Diseases 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Primary Breast Cancer ER+ve 1 Premenopausal Breast Cancer 1 Post Menopausal Women With Early Breast Cancer 1 Patient Acceptance of Health Care 1 Pain 1 Ovarian Neoplasms 1

Interventions

trametinib 1 talimogene laherparepvec 1 spartalizumab 1 pembrolizumab 1 nazartinib 1 exemestane 1 canakinumab 1 Telomerase 1 Tamoxifen 1 Surgical Procedures, Operative 1 Sentinel Lymph Node Biopsy 1 Pemetrexed 1 Paclitaxel 1 Mastectomy, Subcutaneous 1 Mastectomy, Segmental 1 Mammaplasty 1 Brachytherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07499999 2026-03-30

BabyTEARS

Dana-Farber Cancer Institute

Phase 2 Not yet recruiting

Breast Neoplasms, Carcinoma, Ductal

Data powered by HemOnc (CC BY 4.0) Colophon ⚡